E3 Journal of Biotechnology and Pharmaceutical Research

E3 Journal of Biotechnology and Pharmaceutical Research Vol. 4 (5) pp. 81-88, May 2013; © E3 Journals; ISSN 2141-7474

Influence of glycation on low density lipoprotein in diabetic cardiovascular disease patients

Abstract

Cardiovascular disease (CVD) is the major cause of premature death in individuals’ glycated low density lipoproteins (LDL). The potential importance of LDL glycation was observed as an atherogenic modification in diabetic patients. For this purpose the advanced glycation end products (AGEs) levels in all the four groups of cardiovascular diseases patients were analyzed to establish whether glycation is the underlying defect in cardiovascular diseases and this has implications for the development of prevention and treatment strategies. A total of 200 male patients having cardiovascular diseases with type 2 diabetes between the ages of 40-60 and 50 healthy subjects were enrolled in this study. The subjects were divided into five groups. Glycated LDL, which can participate in many of the cellular processes leading to atherosclerosis, generally circulates at higher concentration in diabetic people with cardiovascular diseases. Glycated LDL is the major fundamental factor associated with cardiovascular diseases in the local human population

Keywords: Advanced glycation end products (AGEs), low density lipoproteins (LDL), high density lipoproteins (HDL), cardiovascular diseases (CVD)